Cocktail without hangover: in search for the optimal chemotherapy in the combined management of non-operable esophageal carcinomas

References

• Ferlay J, Soerjomataram I, Ervik M, et al. GLOBOCAN 2012 v1.1, Cancer incidence and mortality worldwide: IARC CancerBase No. 11; 2012.
   Google Scholar
• Wheeler JB, Reed CE. Epidemiology of esophageal cancer. Surg Clin North Am. 2012;92:1077–1087.
   PubMed Web of Science ®Google Scholar
• Enzinger PC, Mayer RJ. Esophageal cancer. N Engl J Med. 2003;349:2241–2252.
   PubMed Web of Science ®Google Scholar
• Husband JE, Reznek RH, McLean D. Imaging in oncology. Oxford: Isis Medical Media; 1998.
   Google Scholar
• Shapiro J, van Lanschot JJ, Hulshof MC, et al. Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): long-term results of a randomised controlled trial. Lancet Oncol. 2015;16:1090–1098.
   PubMed Web of Science ®Google Scholar
• Klevebro F, Johnsen G, Johnson E, et al. Morbidity and mortality after surgery for cancer of the oesophagus and gastro-oesophageal junction: a randomized clinical trial of neoadjuvant chemotherapy vs. neoadjuvant chemoradiation. Eur J Surg Oncol. 2015;41:920–926.
   PubMed Web of Science ®Google Scholar
• Cooper JS, Guo MD, Herskovic A, Radiation Therapy Oncology Group, et al. Chemoradiotherapy of locally advanced esophageal cancer: long-term follow-up of a prospective randomized trial (RTOG 85-01). JAMA. 1999;281:1623–1627.
   PubMed Web of Science ®Google Scholar
• Yang GY, McClosky S, Khushalani NI. Principles of modern radiation techniques for esophageal and gastroesophageal junction cancers. Gastrointest Cancer Res. 2009;3:S6–S10.
   Google Scholar
• Lin JC, Tsai JT, Chang CC, et al. Comparing treatment plan in all locations of esophageal cancer: volumetric modulated arc therapy versus intensity-modulated radiotherapy. Medicine. 2015;94:e750.
   PubMed Web of Science ®Google Scholar
• Gaspar LE, Winter K, Kocha WI, et al. A phase I/II study of external beam radiation, brachytherapy, and concurrent chemotherapy for patients with localized carcinoma of the esophagus (Radiation Therapy Oncology Group Study 9207): final report. Cancer. 2000;88:988–995.
   PubMed Web of Science ®Google Scholar
• Nemoto K, Ogawa Y, Matsushita H, et al. A pilot study of radiation therapy combined with daily low-dose cisplatin for esophageal cancer. Oncol Rep. 2001;8:785–789.
   PubMed Web of Science ®Google Scholar
• Waters JS, Tait D, Cunningham D, et al. A multicentre phase II trial of primary chemotherapy with cisplatin and protracted venous infusion 5-fluorouracil followed by chemoradiation in patients with carcinoma of the oesophagus. Ann Oncol. 2002;13:1763–1770.
   PubMed Web of Science ®Google Scholar
• Harney J, Goodchild K, Phillips H, et al. A phase I/II study of CHARTWEL with concurrent chemotherapy in locally advanced, inoperable carcinoma of the oesophagus. Clin Oncol. 2003;15:109–114.
   Web of Science ®Google Scholar
• Crosby TD, Brewster AE, Borley A, et al. Definitive chemoradiation in patients with inoperable oesophageal carcinoma. Br J Cancer. 2004;90:70–75.
   PubMed Web of Science ®Google Scholar
• Ishida K, Ando N, Yamamoto S, et al. Phase II study of cisplatin and 5-fluorouracil with concurrent radiotherapy in advanced squamous cell carcinoma of the esophagus: a Japan Esophageal Oncology Group (JEOG)/Japan Clinical Oncology Group trial (JCOG9516). Jpn J Clin Oncol. 2004;34:615–619.
   PubMed Web of Science ®Google Scholar
• Brunner TB, Rupp A, Melzner W, et al. Esophageal cancer. A prospective phase II study of concomitant-boost external-beam chemoradiation with a top-up endoluminal boost. Strahlenther Onkol. 2008;184:15–22.
   PubMed Web of Science ®Google Scholar
• Nishimura Y, Mitsumori M, Hiraoka M, et al. A randomized phase II study of cisplatin/5-FU concurrent chemoradiotherapy for esophageal cancer: short-term infusion versus protracted infusion chemotherapy (KROSG0101/JROSG021). Radiother Oncol. 2009;92:260–265.
   PubMed Web of Science ®Google Scholar
• Kato H, Sato A, Fukuda H, et al. A phase II trial of chemoradiotherapy for stage I esophageal squamous cell carcinoma: Japan Clinical Oncology Group Study (JCOG9708). Jpn J Clin Oncol. 2009;39:638–643.
   PubMed Web of Science ®Google Scholar
• Kato K, Muro K, Minashi K, et al. Phase II study of chemoradiotherapy with 5-fluorouracil and cisplatin for Stage II–III esophageal squamous cell carcinoma: JCOG trial (JCOG 9906). Int J Radiat Oncol Biol Phys. 2011;81:684–690.
   PubMed Web of Science ®Google Scholar
• Nishimura Y, Hiraoka M, Koike R, et al. Long-term follow-up of a randomized Phase II study of cisplatin/5-FU concurrent chemoradiotherapy for esophageal cancer (KROSG0101/JROSG021). Jpn J Clin Oncol. 2012;42:807–812.
   PubMed Web of Science ®Google Scholar
• Yamashita H, Omori M, Takenaka R, et al. Involved-field irradiation concurrently combined with nedaplatin/5-fluorouracil for inoperable esophageal cancer on basis of (18)FDG-PET scans: a phase II study. Radiother Oncol. 2014;113:182–187.
   PubMed Web of Science ®Google Scholar
• Ma DY, Tan BX, Liu M, et al. Concurrent three-dimensional conformal radiotherapy and chemotherapy for postoperative recurrence of mediastinal lymph node metastases in patients with esophageal squamous cell carcinoma: a phase 2 single-institution study. Radiat Oncol. 2014;9:28.
   PubMed Web of Science ®Google Scholar
• Shinoda M, Ando N, Kato K, et al. Randomized study of low-dose versus standard-dose chemoradiotherapy for unresectable esophageal squamous cell carcinoma (JCOG0303). Cancer Sci. 2015;106:407–412.
   PubMed Web of Science ®Google Scholar
• Minsky BD, Pajak TF, Ginsberg RJ, et al. INT 0123 (Radiation Therapy Oncology Group 94–05) phase III trial of combined-modality therapy for esophageal cancer: high-dose versus standard-dose radiation therapy. J Clin Oncol. 2002;20:1167–1174.
   PubMed Web of Science ®Google Scholar
• Zhao KL, Shi XH, Jiang GL, et al. Late course accelerated hyperfractionated radiotherapy plus concurrent chemotherapy for squamous cell carcinoma of the esophagus: a phase III randomized study. Int J Radiat Oncol Biol Phys. 2005;62:1014–1020.
   PubMed Web of Science ®Google Scholar
• Crehange G, Maingon P, Peignaux K, et al. Phase III trial of protracted compared with split-course chemoradiation for esophageal carcinoma: federation Francophone de cancerologie digestive 9102. J Clin Oncol. 2007;25:4895–4901.
   PubMed Web of Science ®Google Scholar
• Kumar S, Dimri K, Khurana R, et al. A randomised trial of radiotherapy compared with cisplatin chemo-radiotherapy in patients with unresectable squamous cell cancer of the esophagus. Radiother Oncol. 2007;83:139–147.
   PubMed Web of Science ®Google Scholar
• Milano G, Troger V, Courdi A, et al. Pharmacokinetics of cisplatin given at a daily low dose as a radiosensitiser. Cancer Chemother Pharmacol. 1990;27:55–59.
   PubMed Web of Science ®Google Scholar
• Polee MB, Eskens FA, van der Burg ME, et al. Phase II study of bi-weekly administration of paclitaxel and cisplatin in patients with advanced oesophageal cancer. Br J Cancer. 2002;86:669–673.
   PubMed Web of Science ®Google Scholar
• National comprehensive cancer network, clinical practical guidelines in oncology esophageal and esophagogastric junction cancers (excluding the proximal 5 cm of the stomach) Version 2.2013. 2013: ESOPH-E 6.
   Google Scholar
• Jatoi A, Martenson JA, Foster NR, et al. Paclitaxel, carboplatin, 5-fluorouracil, and radiation for locally advanced esophageal cancer: phase II results of preliminary pharmacologic and molecular efforts to mitigate toxicity and predict outcomes: North Central Cancer Treatment Group (N0044). Am J Clin Oncol. 2007;30:507–513.
   PubMed Web of Science ®Google Scholar
• Seung SK, Smith JW, Molendyk J, et al. Selective dose escalation of chemoradiotherapy for esophageal cancer: role of treatment intensification. Semin Oncol. 2004;31:13–19.
   PubMed Web of Science ®Google Scholar
• Honing J, Smit JK, Muijs CT, et al. A comparison of carboplatin and paclitaxel with cisplatinum and 5-fluorouracil in definitive chemoradiation in esophageal cancer patients. Ann Oncol. 2014;25:638–643.
   PubMed Web of Science ®Google Scholar
• Ajani JA, Winter K, Komaki R, et al. Phase II randomized trial of two nonoperative regimens of induction chemotherapy followed by chemoradiation in patients with localized carcinoma of the esophagus: RTOG 0113. J Clin Oncol. 2008;26:4551–4556.
   PubMed Web of Science ®Google Scholar
• Chiarion-Sileni V, Corti L, Ruol A, et al. Phase II trial of docetaxel, cisplatin and fluorouracil followed by carboplatin and radiotherapy in locally advanced oesophageal cancer. Br J Cancer. 2007;96:432–438.
   PubMed Web of Science ®Google Scholar
• Courrech Staal EF, Aleman BM, van Velthuysen ML, et al. Chemoradiation for esophageal cancer: institutional experience with three different regimens. Am J Clin Oncol. 2011;34:343–349.
   PubMed Web of Science ®Google Scholar
• Burmeister BH, Walpole ET, D'arcy N, et al. A phase II trial of chemoradiation therapy with weekly oxaliplatin and protracted infusion of 5-fluorouracil for esophageal cancer. Invest New Drugs. 2009;27:275–279.
   PubMed Web of Science ®Google Scholar
• Khushalani NI, Leichman CG, Proulx G, et al. Oxaliplatin in combination with protracted-infusion fluorouracil and radiation: report of a clinical trial for patients with esophageal cancer. J Clin Oncol. 2002;20:2844–2850.
   PubMed Web of Science ®Google Scholar
• Conroy T, Yataghene Y, Etienne PL, et al. Phase II randomised trial of chemoradiotherapy with FOLFOX4 or cisplatin plus fluorouracil in oesophageal cancer. Br J Cancer. 2010;103:1349–1355.
   PubMed Web of Science ®Google Scholar
• Conroy T, Galais MP, Raoul JL, et al. Definitive chemoradiotherapy with FOLFOX versus fluorouracil and cisplatin in patients with oesophageal cancer (PRODIGE5/ACCORD17): final results of a randomised, phase 2/3 trial. Lancet Oncol. 2014;15:305–314.
   PubMed Web of Science ®Google Scholar
• Lledo G, Huguet F, Chibaudel B, et al. Chemoradiotherapy with FOLFOX plus cetuximab in locally advanced oesophageal cancer: the GERCOR phase II trial ERaFOX. Eur J Cancer. 2016;56:115–121.
   PubMed Web of Science ®Google Scholar
• Jingu K, Nemoto K, Matsushita H, et al. Results of radiation therapy combined with nedaplatin (cis-diammine-glycoplatinum) and 5-fluorouracil for postoperative locoregional recurrent esophageal cancer. BMC Cancer. 2006;6:50.
   PubMed Web of Science ®Google Scholar
• Sato Y, Takayama T, Sagawa T, et al. A phase I/II study of nedaplatin and 5-fluorouracil with concurrent radiotherapy in patients with esophageal cancer. Cancer Chemother Pharmacol. 2006;58:570–576.
   PubMed Web of Science ®Google Scholar
• Shim HJ, Kim DE, Hwang JE, et al. A phase II study of concurrent chemoradiotherapy with weekly docetaxel and cisplatin in advanced oesophageal cancer. Cancer Chemother Pharmacol. 2012;70:683–690.
   PubMed Web of Science ®Google Scholar
• Shen K, Huang XE, Lu YY, et al. Phase II study of docetaxel (Aisu) combined with three- dimensional conformal external beam radiotherapy in treating patients with inoperable esophageal cancer. Asian Pac J Cancer Prev. 2012;13:6523–6526.
   PubMedGoogle Scholar
• Kodaira T, Fuwa N, Kamata M, et al. Single-institute phase I/II trial of alternating chemoradiotherapy with 5-FU and nedaplatin for esophageal carcinoma. Anticancer Res. 2006;26:471–478.
   PubMed Web of Science ®Google Scholar
• Osawa S, Furuta T, Sugimoto K, et al. Prospective study of daily low-dose nedaplatin and continuous 5-fluorouracil infusion combined with radiation for the treatment of esophageal squamous cell carcinoma. BMC Cancer. 2009;9:408.
   PubMed Web of Science ®Google Scholar
• Li QQ, Liu MZ, Hu YH, et al. Definitive concomitant chemoradiotherapy with docetaxel and cisplatin in squamous esophageal carcinoma. Dis Esophagus. 2010;23:253–259.
   PubMed Web of Science ®Google Scholar
• Higuchi K, Komori S, Tanabe S, et al. Definitive chemoradiation therapy with docetaxel, cisplatin, and 5-fluorouracil (DCF-R) in advanced esophageal cancer: a phase 2 trial (KDOG 0501-P2). Int J Radiat Oncol Biol Phys. 2014;89:872–879.
   PubMed Web of Science ®Google Scholar
• Miyazaki T, Sohda M, Tanaka N, et al. Phase I/II study of docetaxel, cisplatin, and 5-fluorouracil combination chemoradiotherapy in patients with advanced esophageal cancer. Cancer Chemother Pharmacol. 2015;75:449–455.
   PubMed Web of Science ®Google Scholar
• Zhao T, Chen H, Zhang T. Docetaxel and cisplatin concurrent with radiotherapy versus 5-fluorouracil and cisplatin concurrent with radiotherapy in treatment for locally advanced oesophageal squamous cell carcinoma: a randomized clinical study. Med Oncol. 2012;29:3017–3023.
   PubMed Web of Science ®Google Scholar
• Ilson DH. Phase II trial of weekly irinotecan/cisplatin in advanced esophageal cancer. Oncology. 2004;18:22–25.
   PubMedGoogle Scholar
• Michel P, Adenis A, Di Fiore F, et al. Induction cisplatin-irinotecan followed by concurrent cisplatin-irinotecan and radiotherapy without surgery in oesophageal cancer: multicenter phase II FFCD trial. Br J Cancer. 2006;95:705–709.
   PubMed Web of Science ®Google Scholar
• Fu C, Li B, Guo L, et al. Phase II study of concurrent selective lymph node late course accelerated hyper-fractionated radiotherapy and pemetrexed and cisplatin for locally advanced oesophageal squamous cell carcinoma. Br J Radiol. 2014;87:20130656.
   PubMed Web of Science ®Google Scholar
• Bidoli P, Stani SC, De Candis D, et al. Single-agent chemotherapy with vinorelbine for pretreated or metastatic squamous cell carcinoma of the esophagus. Tumori. 2001;87:299–302.
   PubMed Web of Science ®Google Scholar
• Koussis H, Scola A, Bergamo F, et al. Neoadjuvant carboplatin and vinorelbine followed by chemoradiotherapy in locally advanced head and neck or oesophageal squamous cell carcinoma: a phase II study in elderly patients or patients with poor performance status. Anticancer Res. 2008;28:1383–1388.
   PubMed Web of Science ®Google Scholar
• Polee MB, Kok TC, Siersema PD, et al. Phase II study of the combination cisplatin, etoposide, 5-fluorouracil and folinic acid in patients with advanced squamous cell carcinoma of the esophagus. Anticancer Drugs. 2001;12:513–517.
   PubMed Web of Science ®Google Scholar
• Iwase H, Shimada M, Nakamura M, et al. Concurrent chemoradiotherapy for locally advanced and metastatic esophageal cancer: longterm results of a phase II study of UFT/CDDP with radiotherapy. Int J Clin Oncol. 2003;8:305–311.
   PubMedGoogle Scholar
• Iyer R, Chhatrala R, Shefter T, et al. Erlotinib and radiation therapy for elderly patients with esophageal cancer – clinical and correlative results from a prospective multicenter phase 2 trial. Oncology. 2013;85:53–58.
   PubMed Web of Science ®Google Scholar
• Li G, Hu W, Wang J, et al. Phase II study of concurrent chemoradiation in combination with erlotinib for locally advanced esophageal carcinoma. Int J Radiat Oncol Biol Phys. 2010;78:1407–1412.
   PubMed Web of Science ®Google Scholar
• Javle M, Pande A, Iyer R, et al. Pilot study of gefitinib, oxaliplatin, and radiotherapy for esophageal adenocarcinoma: tissue effect predicts clinical response. Am J Clin Oncol. 2008;31:329–334.
   PubMed Web of Science ®Google Scholar
• Chen Y, Wu X, Bu S, et al. Promising outcomes of definitive chemoradiation and cetuximab for patients with esophageal squamous cell carcinoma. Cancer Sci. 2012;103:1979–1984.
   PubMed Web of Science ®Google Scholar
• Crosby T, Hurt CN, Falk S, et al. Chemoradiotherapy with or without cetuximab in patients with oesophageal cancer (SCOPE1): a multicentre, phase 2/3 randomised trial. Lancet Oncol. 2013;14:627–637.
   PubMed Web of Science ®Google Scholar
• Tomblyn MB, Goldman BH, Thomas CR, et al. Cetuximab plus cisplatin, irinotecan, and thoracic radiotherapy as definitive treatment for locally advanced, unresectable esophageal cancer: a phase-II study of the SWOG (S0414). J Thoracic Oncol. 2012;7:906–912.
   PubMed Web of Science ®Google Scholar
• Safran H, Dipetrillo T, Akerman P, et al. Phase I/II study of trastuzumab, paclitaxel, cisplatin and radiation for locally advanced, HER2 overexpressing, esophageal adenocarcinoma. Int J Radiat Oncol Biol Phys. 2007;67:405–409.
   PubMed Web of Science ®Google Scholar
• Bang YJ, Van Cutsem E, Feyereislova A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet. 2010;376:687–697.
   PubMed Web of Science ®Google Scholar
• Anderson SE, Minsky BD, Bains M, et al. Combined modality chemoradiation in elderly oesophageal cancer patients. Br J Cancer. 2007;96:1823–1827.
   PubMed Web of Science ®Google Scholar
• Hayter CR, Huff-Winters C, Paszat L, et al. A prospective trial of short-course radiotherapy plus chemotherapy for palliation of dysphagia from advanced esophageal cancer. Radiother Oncol. 2000;56:329–333.
   PubMed Web of Science ®Google Scholar
• Iwase H, Shimada M, Tsuzuki T, et al. Concurrent chemoradiotherapy with a novel fluoropyrimidine, S-1, and cisplatin for locally advanced esophageal cancer: long-term results of a phase II trial. Oncology. 2013;84:342–349.
   PubMed Web of Science ®Google Scholar
• Cho SH, Shim HJ, Lee SR, et al. Concurrent chemoradiotherapy with S-1 and cisplatin in advanced esophageal cancer. Dis Esophagus. 2008;21:697–703.
   PubMed Web of Science ®Google Scholar
• Matsumoto H, Kubota H, Higashida M, et al. Docetaxel/TS-1 with radiation for unresectable squamous cell carcinoma of the esophagus-a phase II trial. Anticancer Res. 2014;34:3759–3763.
   PubMed Web of Science ®Google Scholar
• Dawson SJ, Michael M, Biagi J, et al. A phase I/II trial of celecoxib with chemotherapy and radiotherapy in the treatment of patients with locally advanced oesophageal cancer. Invest New Drugs. 2007;25:123–129.
   PubMed Web of Science ®Google Scholar
• Sjoquist KM, Burmeister BH, Smithers BM, et al. Survival after neoadjuvant chemotherapy or chemoradiotherapy for resectable oesophageal carcinoma: an updated meta-analysis. Lancet Oncol. 2011;12:681–692.
   PubMed Web of Science ®Google Scholar
• Zhu LL, Yuan L, Wang H, et al. A meta-analysis of concurrent chemoradiotherapy for advanced esophageal cancer. PLoS ONE. 2015;10:e0128616.
   Web of Science ®Google Scholar
• Higuchi K, Koizumi W, Tanabe S, et al. Current management of esophageal squamous-cell carcinoma in Japan and other countries. Gastrointest Cancer Res 2009;3:153–161.
   PubMedGoogle Scholar